These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 26048091)

  • 21. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.
    Balkan B; Kwasnik L; Miserendino R; Holst JJ; Li X
    Diabetologia; 1999 Nov; 42(11):1324-31. PubMed ID: 10550416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate.
    Lee DS; Lee ES; Alam MM; Jang JH; Lee HS; Oh H; Kim YC; Manzoor Z; Koh YS; Kang DG; Lee DH
    Metabolism; 2016 Feb; 65(2):89-101. PubMed ID: 26773932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
    Ahrén B; Foley JE
    Int J Clin Pract Suppl; 2008 Mar; (159):8-14. PubMed ID: 18269436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
    El-Ouaghlidi A; Rehring E; Holst JJ; Schweizer A; Foley J; Holmes D; Nauck MA
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4165-71. PubMed ID: 17698900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways.
    Abdelsalam RM; Safar MM
    J Neurochem; 2015 Jun; 133(5):700-7. PubMed ID: 25752913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
    Omar B; Ahrén B
    Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The scientific evidence: vildagliptin and the benefits of islet enhancement.
    Mathieu C
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():9-17. PubMed ID: 19385979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited.
    Burkey BF; Hoffmann PK; Hassiepen U; Trappe J; Juedes M; Foley JE
    Diabetes Obes Metab; 2008 Nov; 10(11):1057-61. PubMed ID: 18422675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system.
    D'Alessio D; Lu W; Sun W; Zheng S; Yang Q; Seeley R; Woods SC; Tso P
    Am J Physiol Regul Integr Comp Physiol; 2007 Dec; 293(6):R2163-9. PubMed ID: 17898126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised clinical trial: the DPP-4 inhibitor, vildagliptin, inhibits gastric accommodation and increases glucagon-like peptide-1 plasma levels in healthy volunteers.
    Rotondo A; Masuy I; Verbeure W; Biesiekierski JR; Deloose E; Tack J
    Aliment Pharmacol Ther; 2019 Apr; 49(8):997-1004. PubMed ID: 30828846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat.
    Ohlsson L; Kohan AB; Tso P; Ahrén B
    Regul Pept; 2014 Feb; 189():40-5. PubMed ID: 24583245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).
    Brandt I; Joossens J; Chen X; Maes MB; Scharpé S; De Meester I; Lambeir AM
    Biochem Pharmacol; 2005 Jul; 70(1):134-43. PubMed ID: 15907807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice.
    Hartmann B; Thulesen J; Kissow H; Thulesen S; Orskov C; Ropke C; Poulsen SS; Holst JJ
    Endocrinology; 2000 Nov; 141(11):4013-20. PubMed ID: 11089531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
    Lugari R; Dei Cas A; Ugolotti D; Barilli AL; Camellini C; Ganzerla GC; Luciani A; Salerni B; Mittenperger F; Nodari S; Gnudi A; Zandomeneghi R
    Horm Metab Res; 2004 Feb; 36(2):111-5. PubMed ID: 15002062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
    Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
    Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
    Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.